Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study (DVES)
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Disitamab vedotin (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms DVES
Most Recent Events
- 06 Jul 2023 New trial record